SCHEMBL6730179

SCHEMBL6730179

Cc1nc(-c2noc(CO)c2-c2ccc(S(N)(=O)=O)c(F)c2)cs1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 6/20 0.43
PTGS1 P23219 3/20 0.41
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
LMNA P02545 1/20 0.37
HSP90AA1 P07900 1/20 0.37
HSP90AB1 P08238 1/20 0.37
BRD4 O60885 2/20 0.36
PTGES2 Q9H7Z7 1/20 0.36
ALDH1A1 P00352 2/20 0.36
KDM4E B2RXH2 2/20 0.36
BLM P54132 1/20 0.36
POLB P06746 1/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
RECQL P46063 1/20 0.36
ESR2 Q92731 1/20 0.36
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6721391 0.91 PTGS2 (0.43) PTGS2PTGS1MEN1KMT2ALMNA
SCHEMBL6722788 0.91 PIK3CD (0.38) PTGS2MEN1KMT2ALMNAHSP90AA1
SCHEMBL6733423 0.87 PTGS2 (0.40) PTGS2MEN1KMT2ALMNAHSP90AA1
SCHEMBL6723782 0.87 PTGS2 (0.46) PTGS2PTGS1MEN1KMT2ALMNA
SCHEMBL6731267 0.85 LMNA (0.38) PTGS2PTGS1MEN1KMT2ALMNA
SCHEMBL6729542 0.85 PTGS2 (0.43) PTGS2PTGS1BRD4ALDH1A1BRD2
SCHEMBL6721224 0.83 MEN1 (0.51) PTGS2PTGS1MEN1KMT2ALMNA
SCHEMBL6722698 0.83 PTGS2 (0.46) PTGS2PTGS1BRD4ALDH1A1BRD2
SCHEMBL6730176 0.83 PTGS2 (0.42) PTGS2PTGS1MEN1KMT2ALMNA
SCHEMBL6729399 0.83 PTGS2 (0.54) PTGS2PTGS1LMNABRD4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2004-05-13 US disclosed
EP-1296971-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION Pharmacia Corporation (US) 2003-04-02 EP disclosed
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2002-12-05 US disclosed
WO-2001081332-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, FPR1, PTGES2 PTGS2 5/4885PTGS1 4/4885MEN1 4391/4885
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, PTGES2, FPR1 PTGS2 5/4885PTGS1 4/4885MEN1 4477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.